Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 73

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 73
---
 decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering
our business downgrade their evaluations of our shares, the price of our shares could decline. If one or more of these analysts cease
to cover our shares, we could lose visibility in the market for our shares, which in turn could cause our share price to decline.

Raising additional capital would cause dilution to our existing shareholders, and may adversely affect the rights of existing shareholders.

We may seek additional capital
through a combination of private and public equity offerings, debt financings and collaborations, and strategic and licensing arrangements.
To the extent that we raise additional capital through the issuance of equity (such as this offering) or otherwise including through
convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that
adversely affect your rights as a shareholder. Future sales of our Ordinary Shares or of securities convertible into our Ordinary Shares,
or the perception that such sales may occur, could cause immediate dilution and adversely affect the market price of our Ordinary Shares.

Future sales of our Ordinary Shares could reduce the market price of our Ordinary Shares.

If our existing shareholders,
particularly our directors, their affiliates, or our executive officers, sell a substantial number of our Ordinary Shares in the public
market, the market price of our Ordinary Shares could decrease significantly. The perception in the public market that our shareholders
might sell our Ordinary Shares could also depress the market price of our Ordinary Shares and could impair our future ability to obtain
capital, especially through an offering of equity securities.

A majority of our Ordinary
Shares outstanding prior to this offering, the Ordinary Shares issuable upon the exercise of warrants and vested options, and Ordinary
Shares which will be issued as a result of the conversion of the 2020 CLAs, the 2024 CLAs and Preferred Shares that will automatically
convert in connection with this offering will be subject to lock-up agreements that restrict the ability of their holders to transfer
such shares for six (6) months after the date of this prospectus. Consequently, upon expiration of the lock-up agreements, the vast majority
of our Ordinary Shares will be eligible for sale in the public market, of which approximately 1,792,058 Ordinary Shares will be subject
to restrictions on volume and manner of sale pursuant to Rule 144 under the Securities Act of 1933, as amended, or the Securities Act.

We have not paid dividends in the past and do not expect to pay dividends